Compounded vs. FDA-Approved GLP-1 Medications

Learn how compounded GLP-1 medications differ from FDA-approved Wegovy and Zepbound, including quality review, dosing, shortages, and safety.

WEIGHT MANAGEMENTTREATMENT OPTIONS

Sarina Helton, MSN, APRN, FNP-C, CAE-OM Founder, Optima Vida Healthcare

9/18/202611 min read

Compounded vs. FDA-Approved GLP-1 Medications: What Patients Should Know

Compounded GLP-1 medications became widely available when shortages made products such as Wegovy and Zepbound difficult to obtain. This led to a common misconception that compounded semaglutide or tirzepatide is simply a less expensive generic version of the brand-name medication.

It is not.

Compounded medications can meet an important medical need for an individual patient. However, they are not FDA-approved finished products, are not FDA-approved generics, and do not undergo the same premarket review as Wegovy, Zepbound, Ozempic, Mounjaro, Saxenda, Rybelsus, or Foundayo.

The regulatory environment has also changed since the national shortages ended. Understanding the differences in approval, quality oversight, labeling, dosing, and legal availability can help patients interpret claims about compounded GLP-1 medications.

Key Points

Compounded semaglutide and tirzepatide are not FDA-approved generics.
The FDA does not review each finished compounded drug for safety, effectiveness, quality, or labeling before it is dispensed.
Section 503A pharmacies and section 503B outsourcing facilities operate under different requirements, but neither designation means an individual compounded product is FDA-approved.
The resolution of the semaglutide and tirzepatide injection shortages changed when routine copies may qualify for federal compounding exemptions.
Variable vial concentrations and confusion among milligrams, milliliters, and syringe units can contribute to dosing errors.

What Is an FDA-Approved GLP-1 Medication?

FDA approval applies to a specific finished drug product—not merely the name of an active ingredient. The review addresses the product’s:

Safety and effectiveness
Identity, strength, quality, and purity
Formulation and dose accuracy
Manufacturing process and quality controls
Stability and storage requirements
Labeling, packaging, and delivery system
Instructions for administration

FDA-approved GLP-1 and related medications are available for chronic weight management, type 2 diabetes, and certain additional indications. Examples include:

Wegovy: Semaglutide for chronic weight management and other approved indications
Zepbound: Tirzepatide for chronic weight management and other approved indications
Saxenda: Liraglutide for chronic weight management
Foundayo: Orforglipron tablets for chronic weight management
Ozempic: Semaglutide for type 2 diabetes and other approved indications
Mounjaro: Tirzepatide for type 2 diabetes
Rybelsus: Oral semaglutide for type 2 diabetes

Tirzepatide activates both GIP and GLP-1 receptors. Semaglutide, liraglutide, and orforglipron act through the GLP-1 receptor.

For a broader explanation of how clinicians compare approved treatment options, see How Are Anti-Obesity Medications Selected?. Coming soon

What Is a Compounded Medication?

A compounded medication is prepared by a licensed pharmacist, physician, or other legally authorized compounder when applicable federal and state requirements are met. Compounding may address an individual clinical need that an available FDA-approved product cannot meet, such as a medically necessary alternative dosage form or the exclusion of a specific inactive ingredient.

Drug shortages can also affect when certain compounded products may be produced. However, compounding is not a separate FDA pathway for approving routine, mass-marketed copies of commercially available drugs.

A compounded medication is not automatically unsafe. The critical distinction is that the finished compounded product has not undergone FDA premarket review for safety, effectiveness, or quality.

Is Compounded Semaglutide a Generic Version of Wegovy?

No. Compounded semaglutide is not an FDA-approved generic version of Wegovy or Ozempic. Compounded tirzepatide is not a generic version of Zepbound or generic Mounjaro.

An FDA-approved generic drug undergoes FDA review and must satisfy applicable requirements, including pharmaceutical equivalence and bioequivalence to its reference product. A compounded product does not complete that approval process.

The FDA has warned companies against promotional claims suggesting that compounded GLP-1 products are:

Generic versions of FDA-approved medications
The same as or identical to an FDA-approved product
Proven to produce the same clinical results
FDA-approved medications

Even when a compounded drug is described as containing a similarly named active ingredient, that does not establish that the finished product has the same formulation, stability, sterility, absorption, dose accuracy, safety, or clinical performance as an FDA-approved medication.

What Does “Not FDA-Approved” Mean?

“Not FDA-approved” does not mean that the FDA reviewed the finished product and rejected it. It means the product was not submitted and approved through the FDA’s new-drug or generic-drug approval process.

The FDA generally has not verified each compounded product’s:

Stated potency and concentration
Batch-to-batch consistency
Sterility
Stability through its assigned beyond-use date
Clinical performance compared with an approved product
Labeling and administration instructions
Risks and benefits through trials of that exact formulation

Patients and prescribers therefore rely more heavily on the quality systems of the pharmacy or outsourcing facility.

What Is a 503A Compounding Pharmacy?

Section 503A of the Federal Food, Drug, and Cosmetic Act generally applies to traditional compounding by a licensed pharmacist in a state-licensed pharmacy or federal facility, or by a physician, when the statutory conditions are met.

A 503A pharmacy typically:

Compounds medication for an identified patient based on a valid prescription
Is primarily overseen by its state board of pharmacy
Must comply with applicable state laws and compounding standards
Remains subject to relevant federal requirements and FDA oversight
Is restricted from routinely producing drugs that are essentially copies of commercially available products, subject to limited exceptions

Qualifying 503A products are exempt from certain federal requirements, including premarket approval and current good manufacturing practice requirements.

503A describes a legal category. It is not an FDA approval or quality endorsement.

What Is a 503B Outsourcing Facility?

A 503B outsourcing facility registers with the FDA and operates under additional federal requirements. A qualifying facility:

May compound larger batches under permitted circumstances
Is subject to current good manufacturing practice requirements
Must report certain product information to the FDA
Is inspected by the FDA according to a risk-based schedule
Must report certain adverse events
Appears on the FDA’s list of registered outsourcing facilities

Registration does not mean that the FDA approved the facility, approved each compounded drug, or determined that its products are equivalent to FDA-approved medications.

Why Did Compounded GLP-1 Medications Become So Common?

Federal law generally restricts compounding drugs that are essentially copies of commercially available FDA-approved products. When a drug appears on the FDA shortage list, certain copy restrictions may apply differently, allowing qualifying compounders to help address supply problems when all other legal requirements are met.

That shortage-based flexibility is tied to shortage status. It does not create permanent authorization to mass-produce lower-cost copies after a shortage ends.

Are Semaglutide and Tirzepatide Still in Shortage?

The FDA removed tirzepatide injection products from its shortage list on October 2, 2024, and reaffirmed in December 2024 that the shortage was resolved. The FDA declared the semaglutide injection shortage resolved on February 21, 2025. The agency provided limited transition periods for certain compounding activity.

As of August 2026, semaglutide and tirzepatide injection products are not listed as being in shortage. Routine shortage-based production of essentially identical copies is therefore not treated the same way it was during the shortages.

Compounding may remain permissible in specific circumstances when all applicable requirements are satisfied. A lower price alone does not establish an individualized clinical difference or create a shortage exception.

Federal and state compounding requirements can change, and the legality of a particular prescription depends on the drug, formulation, pharmacy, patient-specific circumstances, and law in effect at that time.

Cost may still shape access after a shortage ends. Wegovy and Zepbound Self-Pay Prices in 2026 explains how manufacturer programs differ from insurance coverage and compounded-drug pricing.

Can a Compounded GLP-1 Be Customized?

A compounded medication may be customized when an individual patient has a legitimate clinical need that an available commercial product cannot meet. The rationale is patient-specific and is ordinarily documented by the prescriber.

Marketing language such as “personalized” does not, by itself, establish a clinical need merely because a company:

Selects a dose
Changes the concentration
Uses a vial instead of a pen
Offers a dose outside the approved product’s labeled options
Adds a vitamin without a documented rationale
Charges less than the brand-name product

Adding vitamin B12, glycine, or another ingredient does not automatically make a compounded GLP-1 safer, more effective, or legally necessary. The rationale, compatibility, stability, and evidence for the combination are separate considerations.

What Are Semaglutide Sodium and Semaglutide Acetate?

Semaglutide sodium and semaglutide acetate are salt forms that differ from the active ingredient used in FDA-approved semaglutide medications.

The FDA has stated that it lacks information showing these salt forms have the same chemical and pharmacologic properties as the active ingredient in approved semaglutide products. The agency has also said it is unaware of a lawful basis for using these salt forms in compounding.

A label that states only “semaglutide” may not fully identify whether the ingredient is semaglutide base or a salt form. The exact active ingredient is therefore an important part of the product documentation.

Why Can Compounded Vials Create Dosing Confusion?

FDA-approved pens and tablets come in standardized strengths with product-specific labeling. Compounded injectable medications are often supplied in multidose vials, and concentrations can differ by pharmacy or prescription.

This can create opportunities for error, including:

Confusing milligrams with milliliters
Confusing milliliters with syringe units
Using an incompatible syringe size
Assuming the same number of units applies to every concentration
Reusing instructions from a previous formulation
Miscalculating the volume after a concentration change
Drawing up substantially more medication than intended

The FDA has received reports of compounded semaglutide dosing errors, including overdoses and adverse events requiring hospitalization.

Complete prescription and dispensing information generally identifies the medication, concentration in milligrams per milliliter, prescribed dose in milligrams, injection volume, corresponding syringe markings when applicable, syringe type, administration frequency, beyond-use date, and storage requirements.

An instruction such as “inject 20 units” does not identify the medication dose unless the concentration and syringe type are also known.

Does the Same Number of Units Equal the Same Dose?

Not necessarily. Syringe units measure volume; they do not independently identify the amount of medication in milligrams.

The same number of units drawn from two different concentrations can contain different medication doses. A dosing chart from another patient, pharmacy, vial, or concentration may therefore describe an entirely different dose.

Are Compounded GLP-1 Medications Less Expensive?

Compounded medications often have a lower advertised price than brand-name medications purchased without insurance. However, an advertised price may exclude:

Medical evaluation or membership fees
Shipping and injection supplies
Laboratory testing
Follow-up visits
Dose-based price increases
Cancellation requirements
Manufacturer self-pay programs for FDA-approved products

A meaningful comparison accounts for the complete monthly expense, the medication and concentration supplied, required services, and differences in regulatory and quality oversight. Price alone does not establish product equivalence.

Are Compounded GLP-1 Medications More Effective?

There is no reliable basis for assuming that a compounded GLP-1 medication is more effective than an FDA-approved product containing the same general active ingredient.

The clinical trials supporting Wegovy, Zepbound, and other approved drugs evaluated the manufacturers’ specific finished products using defined formulations, doses, delivery systems, schedules, and quality controls. Their results cannot automatically be applied to every compounded formulation.

Claims that a compounded product works faster, produces greater weight loss, causes fewer adverse effects, or is clinically equivalent to an FDA-approved product require evidence from the exact formulation being promoted.

Do Compounded Medications Have Different Risks?

The expected adverse effects associated with the active medication may still occur. Depending on the drug, these can include nausea, vomiting, diarrhea, constipation, reflux, abdominal discomfort, dehydration, gallbladder complications, pancreatitis, and hypoglycemia when combined with certain diabetes medications.

A compounded product may also carry risks involving:

Incorrect potency or concentration
Contamination or inadequate sterility
Stability or storage problems
Dose-measurement errors
Added ingredients
An unexpected active ingredient
Fraudulent or inaccurate labeling

Unexpected reactions and suspected product-quality problems can be reported through the FDA’s MedWatch program in addition to the usual clinical and pharmacy reporting channels.

For more context on class-related adverse effects, see Most Common GLP-1 Side Effects.

What About Counterfeit GLP-1 Medication?

Counterfeit medication is different from legitimate pharmacy compounding. A counterfeit or fraudulent product may falsely claim to be an authentic brand medication, originate from a legitimate manufacturer or pharmacy, or move through an authorized distribution channel.

Counterfeit products may contain too much, too little, or none of the expected ingredient. They may contain another drug, contaminants, or harmful substances.

The FDA has identified counterfeit Ozempic and fraudulent products labeled as compounded semaglutide or tirzepatide. Products marketed through informal social-media sellers, online marketplaces, peptide websites, or as “research use only” are not equivalent to prescription medications dispensed by a licensed pharmacy.

How Are Pharmacy Credentials Described?

Information used to identify a compounding pharmacy includes its full legal name, physical address, telephone number, state pharmacy-license number, the states where it is licensed to dispense, and whether it operates under section 503A or as a registered 503B outsourcing facility.

State boards of pharmacy provide pharmacy license information. The FDA publishes a list of registered 503B outsourcing facilities.

The phrase “FDA-approved pharmacy” is inaccurate. State authorities license pharmacies, while qualifying outsourcing facilities register with the FDA. The FDA does not approve compounding pharmacies or their individual compounded products.

Information Relevant to a Compounded GLP-1 Prescription

Key product information includes:

The clinical reason a compounded product is being considered
The exact active ingredient and any additional ingredients
Whether semaglutide base or a salt form is used
The compounding pharmacy’s name and licensing information
Whether the source is a 503A pharmacy or 503B outsourcing facility
The concentration in milligrams per milliliter
The prescribed dose in milligrams
The injection volume and syringe type, when applicable
Storage requirements and beyond-use date
Procedures for products that arrive warm, damaged, cloudy, contaminated, or mislabeled
Contact information for adverse effects, dosing questions, or suspected errors

Incomplete or inconsistent information about the ingredient, concentration, dose, syringe markings, storage, or pharmacy can increase the risk of medication errors.

Does FDA-Approved Mean Risk-Free?

No. FDA-approved GLP-1 medications can cause significant adverse effects and are not appropriate for everyone.

Depending on the medication, important risks can include severe gastrointestinal symptoms, dehydration and kidney injury, gallbladder disease, pancreatitis, hypoglycemia with insulin or sulfonylureas, diabetic retinopathy complications, allergic reactions, fetal harm during pregnancy, and thyroid C-cell tumor warnings.

FDA approval means the FDA has evaluated the specific product’s benefits, risks, manufacturing, and labeling. It does not mean the medication has no risks or is appropriate for every patient.

The Bottom Line

Compounded semaglutide and tirzepatide are not FDA-approved generic versions of Wegovy, Ozempic, Zepbound, or Mounjaro.

FDA-approved products undergo premarket review for safety, effectiveness, quality, manufacturing, and labeling. Compounded finished products do not. Their formulations and concentrations may vary, and compounded vials can create additional opportunities for measurement errors.

The national semaglutide and tirzepatide injection shortages have been resolved, so shortage-based compounding is now more restricted. Compounding may still serve a legitimate patient-specific need when all applicable legal requirements are met.

A lower price or a claim that a product is “personalized” does not establish that it is generic, equivalent, or more effective than an FDA-approved medication.

Frequently Asked Questions

Are compounded GLP-1 medications generic drugs?

No. A compounded GLP-1 medication has not completed the FDA generic-drug approval process and should not be marketed as generic Wegovy, Ozempic, Zepbound, or Mounjaro.

Are compounded GLP-1 medications FDA-approved?

No. The FDA does not approve an individual compounded finished product before it is dispensed. A pharmacy license or 503B registration also does not make the drug FDA-approved.

Is GLP-1 compounding prohibited now that shortages have ended?

Not in every circumstance. Compounding may still qualify for federal exemptions when the applicable legal conditions are met, including certain documented patient-specific needs. The end of a shortage does, however, restrict routine shortage-based production of essentially identical copies.

What is the difference between a 503A pharmacy and a 503B outsourcing facility?

A 503A pharmacy generally compounds for an identified patient under a prescription and is primarily overseen by its state board of pharmacy. A 503B outsourcing facility registers with the FDA, may produce permitted batches, and is subject to additional federal manufacturing, inspection, reporting, and labeling requirements.

Does “FDA-registered pharmacy” mean its medications are FDA-approved?

No. Registration describes the facility’s regulatory status. It does not indicate FDA approval of the facility’s individual compounded products.

Are syringe units the same as milligrams?

No. Syringe units describe volume markings. The milligram dose depends on the medication concentration, so the same number of units can represent different doses in different vials.

Learn More About Medical Weight Management

At Optima Vida Healthcare (OVH), treatment options are evaluated according to health history, previous treatment, medication response, side effects, goals, clinical appropriateness, and current legal availability.

When a compounded medication is considered, OVH explains the product source, clinical rationale, dosing information, limitations, and potential risks. Completing an evaluation does not guarantee a prescription or access to a compounded medication.

Start a Weight-Management Evaluation →

Visit ovhmed.com for more information →

Prescription medication is not guaranteed. Prescribing decisions are made by a licensed healthcare professional after an appropriate clinical evaluation.

Written by and clinically reviewed for accuracy by:

Sarina Helton, MSN, APRN, FNP-C, CAE-OM

Sarina Helton, MSN, APRN, FNP-C, CAE-OM, is a board-certified family nurse practitioner and founder of Optima Vida Healthcare. Her clinical focus includes obesity medicine, medical weight management, metabolic health, hormone-related concerns, sexual health, hair loss, and evidence-based telehealth care.

Last medically reviewed: August 2026

Ready to Explore Medical Weight Management?

Optima Vida Healthcare provides individualized weight-management evaluations that consider current health, weight history, previous treatment, medications, and long-term goals.

Start Your Weight-Management Evaluation →

Learn more at www.ovhmed.com.

Prescription medication is not guaranteed and is prescribed only when clinically appropriate after evaluation by a licensed healthcare professional.

Educational Disclaimer

This article is provided for general educational purposes only. It does not provide individualized medical or legal advice, recommend a specific medication or pharmacy, establish that compounding is appropriate or lawful in an individual case, or replace evaluation by a qualified healthcare professional. Federal and state requirements may change.

Sources

SEO title: Compounded vs. FDA-Approved GLP-1 Medications
Meta description: Learn how compounded GLP-1 medications differ from FDA-approved Wegovy and Zepbound, including quality review, dosing, shortages, and safety.
URL slug: compounded-vs-fda-approved-glp-1-medications
Focus keyphrase: compounded vs. FDA-approved GLP-1 medications
Secondary keywords: compounded semaglutide safety, compounded tirzepatide, generic Wegovy, generic Zepbound, 503A vs. 503B pharmacy, GLP-1 compounding rules
Excerpt: Compounded semaglutide and tirzepatide are not FDA-approved generics. Learn how approval, quality oversight, dosing, shortages, and pharmacy categories differ.